138530-94-6 | (R)-Lansoprazole

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$6.00	$4.00
250mg	98%	in stock	$11.00	$8.00
5g	98%	in stock	$100.00	$70.00

Description

• Catalog Number: AD54870
• Chemical Name: (R)-Lansoprazole
• CAS Number: 138530-94-6
• Molecular Formula: C16H14F3N3O2S
• Molecular Weight: 369.3615
• MDL Number: MFCD13196699
• SMILES: O=[S@@](c1nc2c([nH]1)cccc2)Cc1nccc(c1C)OCC(F)(F)F

Computed Properties

• Complexity: 480
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 25
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 5
• XLogP3: 2.8

Literature

• The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease.

  Therapeutic advances in gastroenterology 20170201

• Managing gastroesophageal reflux disease - comparative efficacy and outcomes of dexlansoprazole MR.

  Therapeutics and clinical risk management 20150101

• Dexlansoprazole - a new-generation proton pump inhibitor.

  Przeglad gastroenterologiczny 20150101

• Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.

  Drug metabolism and disposition: the biological fate of chemicals 20120901

• Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects.

  Clinical drug investigation 20120501

• A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.

  Journal of the American College of Cardiology 20120403

• Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20120301

• Development and validation of a highly sensitive LC-MS/MS method for quantitation of dexlansoprazole in human plasma: application to a human pharmacokinetic study.

  Biomedical chromatography : BMC 20120201

• Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.

  Journal of pediatric gastroenterology and nutrition 20120101

• Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data.

  The American journal of gastroenterology 20111101

• Dexlansoprazole MR: a review.

  Annals of medicine 20110801

• Dexlansoprazole MR for the management of gastroesophageal reflux disease.

  Expert review of gastroenterology & hepatology 20110801

• The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.

  The American journal of gastroenterology 20110301

• The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.

  Alimentary pharmacology & therapeutics 20110201

• Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.

  Drugs 20100820

• Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.

  Clinical therapeutics 20100801

• The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor.

  Alimentary pharmacology & therapeutics 20100501

• Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.

  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20100501

• Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.

  The Annals of pharmacotherapy 20100501

• Dexlansoprazole for the treatment of esophagitis and GERD.

  Drugs of today (Barcelona, Spain : 1998) 20100201

• Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants.

  Journal of clinical pharmacology 20091201

• New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II.

  Current drug metabolism 20091201

• Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.

  Alimentary pharmacology & therapeutics 20091115

• Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.

  Alimentary pharmacology & therapeutics 20091101

• Dexlansoprazole MR.

  Expert opinion on pharmacotherapy 20091001

• Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.

  Alimentary pharmacology & therapeutics 20090501

• Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.

  Alimentary pharmacology & therapeutics 20090415

• Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.

  Alimentary pharmacology & therapeutics 20090401

• Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.

  Alimentary pharmacology & therapeutics 20090401

• Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.

  Journal of clinical pharmacology 20090401

• Dexlansoprazole (Kapidex) for GERD and erosive esophagitis.

  The Medical letter on drugs and therapeutics 20090323

• Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.

  Current medical research and opinion 20090301

• Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.

  Clinical drug investigation 20090101

• Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.

  Current medicinal chemistry 20090101

• Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.

  Clinical and experimental gastroenterology 20090101

• Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis.

  Current opinion in investigational drugs (London, England : 2000) 20081001

• Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers.

  European journal of clinical pharmacology 20080501

• Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.

  International journal of clinical pharmacology and therapeutics 20061201

• Enantioselective disposition of lansoprazole and rabeprazole in human plasma.

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20060601

• Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole.

  Xenobiotica; the fate of foreign compounds in biological systems 20060101

• Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.

  British journal of clinical pharmacology 20050701

• Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.

  Chirality 20050601

• Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.

  Xenobiotica; the fate of foreign compounds in biological systems 20050501

• Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.

  Drug metabolism and disposition: the biological fate of chemicals 20050201

• Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.

  Xenobiotica; the fate of foreign compounds in biological systems 20050101

• Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.

  European journal of clinical pharmacology 20041101

• Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.

  Clinical pharmacology and therapeutics 20020701